Washington · Nonprofit
RIVKIN CENTER FOR OVARIAN CANCER
RIVKIN CENTER FOR OVARIAN CANCER (Washington) receives grants from 42 organizations whose IRS filings report $2,778,282 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($606,669). 27 of them have funded it in more than one year, and 75% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2024
- $1.7M
- Funders on record
- 42
- Grants received
- $2.8M
- Net assets
- $1.9M
What Rivkin Center for Ovarian Cancer does
Mission
We envision a world where women live longer and healthier lives because ovarian cancer can be prevented, caught early, or cured.
As stated on its FY2024 Form 990.
Programs
On its FY2024 return the organization reported a significant change in how it conducts a program.
On april 1, 2025, the rivkin center will combine with the ovarian cancer research alliance (ocra), ensuring that our mission to end ovarian cancer in our lifetimes will continue to grow and be realized. They also have had a three-decade commitment to funding ovarian cancer research. Ocra's ability to secure funding through government grants and partnerships with biotech companies makes them a powerful partner in amplifying our shared mission. Partnership with ocra will ensure sustainable, long-term investments in the ovarian cancer research that has always been the purpose of our work. This partnership represents a uniting of strengths: ocra has recognized the rivkin center's unique expertise in identifying and funding early-stage, innovative research that often leads to much larger federal grants. In turn, we are honored to partner with an organization that has already invested $128m toward our shared goal of ending ovarian cancer. Ocra also has trusted information and resources to support the ovarian cancer community - patients, survivors, families, advocates, and medical professionals. As part of this transition: - the rivkin center will retire as a separate entity on april 1, 2025 2025 scientific grants will be announced in march 2025 as planned - ocra will continue to award the rivkin pilot grants with around $400k a year dedicated to supporting new ideas in ovarian cancer research throughout the world - the summerun will continue! The 2025 summerun will be held july 13…
Its own explanation, from Schedule O of that return (Part III, line 3).
The rivkin center's programmatic work underwent dynamic change in 2024, and even bigger changes are coming for 2025.for three decades, the rivkin center's scientific grant program has used a seed-funding approach that launches promising new research and researchers throughout the world. After pausing new grants in 2023, the rivkin center funded two $75k pilot study awards in 2024. The rivkin center and washington state's andy hill cancer research endowment (care) fund also created a public-private partnership to jointly support $1m in ovarian cancer research in washington state. In 2024, the first two grants totaling $400k were awarded; $600k in grants will be awarded in 2025. By the end of 2024, the rivkin center had raised its $500k in private matching funds. Ovarian cancer is underfunded by federal funding agencies when compared to other cancers, despite it still having no universal screening tool and being the deadliest gynecological cancer. For every dollar invested by the rivkin center, our awardees, on average, leverage another $17.30 from other funding sources to further their ovarian cancer research.
$290,470 spentof which $290,470 as grants45% of program spendingIn september 2024, the rivkin center hosted the 15th biennial ovarian cancer research symposium, bringing together nearly 250 researchers and clinicians from 11 countries who came to learn about the latest in ovarian cancer research. The event hosted a session with patient advocates; scientific sessions covered the biology of ovarian cancer, prevention, early detection, & interception, emerging therapeutics, novel immunotherapies, and healthcare disparities. On april 30, 2024, the rivkin center ended its education program focused on ovarian and breast cancer education and returned to a sole focus on ovarian cancer - both research grants and better support for those diagnosed with ovarian cancer in the pacific northwest. From january to march 2024 the education team supported 15 college-campus workshops and eight puget sound community workshops. Community workshops were held in coordination with mercy housing, mary's place, familyworks, washington rhinestone club, seattle jewish festival and herzl ner tamid and reached primarily participants who belong to historically under-resourced/underrepresented groups.
$360,801 spent$157,825 earned by the program55% of program spending
The 2 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $651,271.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2018 to 2019, from $2.6M to $1.9M (−30%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2024 6%. Grants only. Government contracts and fees sit inside program revenue.
90% of RIVKIN CENTER FOR OVARIAN CANCER’s revenue is contributions — more donation-reliant than the typical peer (51% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Molly O'Connor
CEO
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 10 funders to 16 funders, grant income rose $77k → $373k.
19 of 42 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 75% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of RIVKIN CENTER FOR OVARIAN CANCER’s funders (the co-funder graph). Top 30 of 42 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
RIVKIN CENTER FOR OVARIAN CANCER has a broad base — no single funder exceeds 22% of grant income, and it takes 3 funders to reach half.
the vertical line marks half of all grant income — 3 funders to its left
82% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund RIVKIN CENTER FOR OVARIAN CANCER.
Largest funder’s share by year: 2017 19% · 2018 56% · 2019 24% · 2020 29% · 2021 23% · 2022 30% · 2023 28% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
41% of RIVKIN CENTER FOR OVARIAN CANCER's funders are still giving 3 years after their first grant; 64% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
75% of RIVKIN CENTER FOR OVARIAN CANCER's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $692k that is directly attributable, 96% of it comes from Washington funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $2.1M arriving through sponsors registered in 13 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
RIVKIN CENTER FOR OVARIAN CANCER holds deeper cash reserves than three-quarters of the 8,121 health nonprofits its size.
this organization peer median middle 50% of peers· 8,121 health nonprofits $1M–$10M, FY2024
Organizations like RIVKIN CENTER FOR OVARIAN CANCER
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Washington
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
39% of spending goes to programs.
Governance
Public support
97%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for RIVKIN CENTER FOR OVARIAN CANCER: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds RIVKIN CENTER FOR OVARIAN CANCER?
- RIVKIN CENTER FOR OVARIAN CANCER (Washington) receives grants from 42 organizations whose IRS filings report $2,778,282 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($606,669). 27 of them have funded it in more than one year, and 75% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does RIVKIN CENTER FOR OVARIAN CANCER have?
- IRS filings report 42 organizations giving $2,778,282 in grants to RIVKIN CENTER FOR OVARIAN CANCER, 27 of which have funded it in more than one year.
- Who is the largest funder of RIVKIN CENTER FOR OVARIAN CANCER?
- FIDELITY INVESTMENTS CHARITABLE GIFT FUND is the largest funder on record, with $606,669 in grants. The full list of funders is on this page.
- How can an organization like RIVKIN CENTER FOR OVARIAN CANCER find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Washington. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 42 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing